GSK plots big launches in emerging markets

GlaxoSmithKline is preparing to launch its smoking-cessation products in as many as 20 new emerging markets--including China, India and Russia--in another sign of the British drugmaker's desire to build sales in the developing world. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.